Mesa Laboratories, Inc. (MLAB)

In the past six months, Mesa Laboratories' stock experienced several notable events. The stock traded up 9.1% on February 4, 2026, following a stronger-than-expected earnings report. A quarterly dividend of $0.16 was announced. Analyst ratings changed, with Wall Street Zen upgrading shares to a "buy" rating, Zacks Research upgrading to a "hold" rating, Wells Fargo & Company raising their target price, and Weiss Ratings restating a "sell (d)" rating. Mesa Laboratories announced results for its second and third fiscal quarters, with revenues and operating income increasing. As of February 6, 2026, the closing stock price was $93.27, with a 46.95% increase over the last 6 months, but a -36.89% change over the past year.

While explicit seasonal patterns are not detailed for all products, Mesa Laboratories' operations are affected by global health crises and macroeconomic uncertainties, impacting demand for certain products. The Clinical Genomics division in China experienced a significant revenue decline, suggesting regional demand fluctuations. The company aims to reduce its past due backlog during the first two quarters of FY26, indicating some cyclicality in order fulfillment. Some demand seasonality might exist, though specific product-level seasonality is not detailed.

Mesa Laboratories, Inc. is a global provider of life sciences tools and quality control products and services, operating within the technology sector, specifically the hardware industry. The company's business model is structured around four main divisions: Sterilization and Disinfection Control (SDC), Clinical Genomics (CG), Biopharmaceutical Development (BPD), and Calibration Solutions (CS). The SDC segment offers indicators and testing services for sterilization and disinfection processes. The CG division provides genetic analysis tools and consumables. The BPD segment offers automated systems for protein analysis and peptide synthesis solutions. The CS division provides quality control products for measuring and calibrating critical parameters.

Mesa Laboratories, Inc. operates globally, developing, designing, manufacturing, selling, and servicing its products and services across North America, Europe, the Asia Pacific, and internationally. The company has offices or operations in North America, Europe, and Asia.

Mesa Laboratories is recognized as a global leader in providing essential quality control solutions for highly regulated sectors. The company's specialized product portfolio fosters strong customer loyalty, and it emphasizes its commitment to "Protecting the Vulnerable®". The company holds certifications such as ISO/IEC 13485:2016, FDA CSA International, and ISO/IEC 17025:2017, contributing to a strong reputation for quality and compliance. A significant revenue decline in the Clinical Genomics division in China and macroeconomic uncertainties have impacted the company.

Mesa Laboratories, Inc. has significant institutional ownership, with 362 institutional owners and shareholders holding 90.60% of the company's stock. Major institutional owners include Conestoga Capital Advisors, LLC, BlackRock, Inc., and The Vanguard Group, Inc. Individual insider ownership is approximately 3.12% of the company's stock. Recent insider transactions in June 2025 involved sales by SVP Operations Brian David Archbold and CFO John Sakys, and both buy and sell transactions by CEO, President & Director Gary Owens.